Calidi Biotherapeutics (CLDI) Research & Development (2022 - 2025)

Calidi Biotherapeutics has reported Research & Development for 4 years, with the latest figure at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development rose 29.92% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $9.7 million (up 9.68% YoY), and the FY2025 full-year result was $9.7 million, up 9.68% from the prior year.
• Research & Development for Q4 2025 stood at $2.4 million, roughly flat from $2.4 million in the prior quarter.
• The five-year high for Research & Development was $4.0 million in Q4 2023, with the low at $1.8 million in Q4 2024.
• Average Research & Development over 4 years is $2.6 million, with a median of $2.4 million recorded in 2025.
• Year-over-year, Research & Development soared 74.9% in 2023 and slumped 54.14% in 2024.
• Tracing CLDI's Research & Development over 4 years: stood at $2.3 million in 2022, then soared by 74.9% to $4.0 million in 2023, then tumbled by 54.14% to $1.8 million in 2024, then advanced by 29.92% to $2.4 million in 2025.
• The last three Research & Development figures came in at $2.4 million (Q4 2025), $2.4 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.

Peer Comparison